News Sentiment

GRCL sentiment intelligence

Gracell Biotechnologies Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 67 Constructive news tone 31 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.25 Week of 19 Jun 2026
Weighted tone 67/100

Constructive news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

72/100 classification confidence.

Company focus 24

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Gracell Biotechnologies Inc. v. Alpine Global Management LLC: Discovery Application (Cayman Islands)

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 72/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend active 0.0% over four weeks
Fair value 81.9% Materially above fair value
Sentiment confirms active trend Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 11
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 24
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
GlobeNewswire 3
BioSpace 3
simplywall.st 2
Pharmaceutical Technology 2
Stock Titan 2
AstraZeneca 2
PR Newswire 2

Event Lens

What the news is about

Classified themes
Market update 10
Deals and strategy 9
Earnings 7
Regulatory and legal 3
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 31
OffshoreAlert Direct company coverage

Gracell Biotechnologies Inc. v. Alpine Global Management LLC: Discovery Application (Cayman Islands)

This article details a discovery application filed by Gracell Biotechnologies Inc. against Alpine Global Management LLC in the U.S. District Court for the Southern District of New York. The application seeks discovery for an "appraisal proceeding" in the Cayman Islands related to

Tone
Neutral 50/100
Event
Market update
Published
22 Apr 2024 02:09
Source
OffshoreAlert
Contract Pharma Direct company coverage

AstraZeneca Acquires Gracell Biotechnologies

AstraZeneca has completed its acquisition of Gracell Biotechnologies Inc., a biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. This acquisition integrates Gracell's clinical-stage CAR-T therapy, GC012F, into AstraZeneca's pipeline, targe

Tone
Positive 72/100
Event
Deals and strategy
Published
23 Feb 2024 00:00
Source
Contract Pharma
Pharmaceutical Technology Direct company coverage

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca has finalized its $1.2bn acquisition of China-based biopharmaceutical company Gracell Biotechnologies, making Gracell a wholly owned subsidiary. This strategic move aims to bolster AstraZeneca's cell therapy pipeline with treatments for cancer and autoimmune diseases,

Tone
Positive 70/100
Event
Deals and strategy
Published
23 Feb 2024 00:00
Source
Pharmaceutical Technology
Stock Titan Direct company coverage

Gracell Biotechnologies Acquisition Completed

Gracell Biotechnologies announced today the completion of its acquisition by AstraZeneca. As a result, Gracell is no longer a publicly traded company and is now a wholly-owned subsidiary of AstraZeneca. Shareholders will receive $2.00 per share in cash and one contingent value ri

Tone
Negative 39/100
Event
Deals and strategy
Published
22 Feb 2024 04:39
Source
Stock Titan
AstraZeneca Direct company coverage

Acquisition of Gracell completed

AstraZeneca announced the successful completion of its acquisition of Gracell Biotechnologies Inc. This acquisition enhances AstraZeneca's cell therapy pipeline with GC012F, a clinical-stage CAR-T therapy for multiple myeloma and autoimmune diseases. Gracell will now operate as a

Tone
Positive 70/100
Event
Deals and strategy
Published
22 Feb 2024 02:59
Source
AstraZeneca
Stock Titan Direct company coverage

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

Gracell Biotechnologies announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of GC012F, its FasTCAR-T cell therapy, for the early-line treatment of multiple myeloma (ELMM). This marks the third U.S. IND clearance for GC012

Tone
Positive 71/100
Event
Regulatory and legal
Published
29 Jan 2024 21:51
Source
Stock Titan
Pharmaceutical Executive Direct company coverage

AstraZeneca Bolsters Cellular Therapy Pipeline With Acquisition of Gracell Biotechnologies

AstraZeneca is acquiring Gracell Biotechnologies Inc. for a deal potentially worth up to $1.2 billion, aiming to enhance its cellular therapy pipeline. The acquisition includes Gracell's FasTCAR platform, which is expected to improve the efficacy of CAR T-cell therapies and accel

Tone
Positive 73/100
Event
Deals and strategy
Published
02 Jan 2024 00:00
Source
Pharmaceutical Executive
Pharmaceutical Technology Direct company coverage

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

AstraZeneca has signed a definitive agreement to acquire Gracell Biotechnologies, a China-based CAR T-cell therapy biotech, for approximately $1.2 billion in combined upfront and potential contingent value payments. This acquisition aims to expand AstraZeneca's portfolio in chime

Tone
Positive 71/100
Event
Deals and strategy
Published
27 Dec 2023 14:46
Source
Pharmaceutical Technology
AstraZeneca Direct company coverage

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company specializing in innovative cell therapies. This acquisition will expand AstraZeneca's cell therapy pipeline with GC012F, a novel CAR-T therapy ta

Tone
Positive 74/100
Event
Deals and strategy
Published
26 Dec 2023 14:58
Source
AstraZeneca
GlobeNewswire Direct company coverage

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

AstraZeneca announced its intent to acquire Gracell Biotechnologies, a clinical-stage biopharmaceutical company focused on cell therapies. The acquisition, valued at up to $1.2 billion, targets Gracell's innovative FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell th

Tone
Positive 73/100
Event
Deals and strategy
Published
26 Dec 2023 08:10
Source
GlobeNewswire
GlobeNewswire Direct company coverage

Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

Gracell Biotechnologies Inc. (NASDAQ: GRCL), a clinical-stage biopharmaceutical company, announced its participation in the inaugural Cell Therapy for Autoimmune Disease Summit. The company's Chief Business Officer, Dr. Samuel Zhang, will present on developing next-generation CAR

Tone
Positive 72/100
Event
Market update
Published
16 Nov 2023 17:09
Source
GlobeNewswire
CGTLive® Direct company coverage

Gracell’s BCMA/CD19 CAR-T GC012F Achieves 100% Stringent CR Rate in Newly Diagnosed Multiple Myeloma

Gracell Biotechnologies' investigational CAR-T therapy, GC012F, has demonstrated a 100% stringent complete response (sCR) rate in newly diagnosed multiple myeloma (NDMM) patients during a phase 1 clinical trial. All 19 patients achieved sCR with minimal residual disease negativit

Tone
Positive 90/100
Event
Regulatory and legal
Published
02 Oct 2023 18:08
Source
CGTLive®
Market source Direct company coverage

Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders

Dr. William Cao, Founder, Chairman, and CEO of Gracell Biotechnologies, has been named to the PharmaVoice 100, an honor recognizing inspiring leaders in the life sciences industry. This recognition highlights his over 30 years of experience and Gracell's commitment to developing

Tone
Positive 74/100
Event
Market update
Published
19 Sep 2023 03:10
Source
Market source
Market source Direct company coverage

RA Capital Management, L.P. Acquires Significant Stake in Gracell Biotechnologies Inc.

RA Capital Management, L.P. has acquired a significant stake in Gracell Biotechnologies Inc., purchasing over 48 million shares at $3.75 each, now holding 9.99% of the company's equity. This strategic investment by the Boston-based firm in the clinical-stage biopharmaceutical com

Tone
Neutral 50/100
Event
Deals and strategy
Published
21 Aug 2023 05:09
Source
Market source
Pharma Voice Direct company coverage

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

Gracell Biotechnologies is developing CAR-T cell therapies aiming to solve manufacturing bottlenecks, reduce costs, and enable first-line treatment for solid tumors. The company's FasTCAR platform significantly shortens manufacturing time, and recent positive Phase 1 data for GC0

Tone
Positive 90/100
Event
Market update
Published
09 Jan 2023 06:57
Source
Pharma Voice
BioSpace Direct company coverage

Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

Gracell Biotechnologies Inc. announced its FasTCAR Autologous CAR-T Platform won the Biotech Innovation category at the 2022 Fierce Life Sciences Innovation Awards. The FasTCAR platform enables next-day manufacturing for CAR-T cell therapies, aiming to improve accessibility, redu

Tone
Positive 90/100
Event
Market update
Published
16 Nov 2022 07:09
Source
BioSpace
BioSpace Direct company coverage

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Gracell Biotechnologies has appointed Dr. Wendy Li as its new Chief Medical Officer. Dr. Li brings over 20 years of experience in oncology clinical development, medical affairs, and U.S. regulatory processes from various pharmaceutical companies. In her new role, she will oversee

Tone
Positive 70/100
Event
Regulatory and legal
Published
01 Aug 2022 12:10
Source
BioSpace
GlobeNewswire Direct company coverage

Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

Gracell Biotechnologies Inc. announced its participation in two upcoming virtual investor conferences: the Jefferies China Biotech Summit and the Citi China Investor Conference 2021. The company will engage in one-on-one and small group meetings, and a fireside chat at the Jeffer

Tone
Neutral 50/100
Event
Market update
Published
15 Oct 2021 08:30
Source
GlobeNewswire
PR Newswire Direct company coverage

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

Gracell Biotechnologies has signed an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2 (CLDN18.2) for solid tumors. This collaboration aims to combine Gracell's expertise in immune cell therapy with FutureGen's

Tone
Positive 91/100
Event
Market update
Published
16 Aug 2021 19:45
Source
PR Newswire